Unknown

Dataset Information

0

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.


ABSTRACT: Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.Tumor tissue from 257 patients with ER-positive breast cancer treated with tamoxifen was used for determination of the best threshold for immunohistochemical Bcl-2 assessment as prognostic marker. Subsequently, samples from the Danish patients of the randomized clinical trial BIG 1-98 comprising 1191 ER-positive patients treated with tamoxifen, letrozole or a sequence of the two were immunohistochemically stained for Bcl-2 to further explore the prognostic value of Bcl-2.Two Bcl-2 levels were found to divide the population of the primary study into significantly different groups according to disease-free survival (DFS). Multivariate analysis confirmed the significance of the lowest level, and showed Bcl-2 to be an independent prognostic marker. Analysis of the Danish cohort of the BIG 1-98 confirmed that Bcl-2 was a significant predictor of DFS, independent of known prognostic markers. However, in an additional analysis of a subset of the Danish cohort of BIG 1-98 including only HER-2 normal patients, the effect of Bcl-2 was not statistically significant.Low Bcl-2 can predict poor outcome of patients with ER-positive tumors treated with adjuvant endocrine therapy, whereas the use of Bcl-2 for determination of addition of chemotherapy was not supported by this study.

SUBMITTER: Larsen MS 

PROVIDER: S-EPMC3744229 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.

Larsen Mathilde S MS   Bjerre Karsten K   Giobbie-Hurder Anita A   Lænkholm Anne-Vibeke AV   Henriksen Katrine L KL   Ejlertsen Bent B   Lykkesfeldt Anne E AE   Rasmussen Birgitte B BB  

Acta oncologica (Stockholm, Sweden) 20120330 6


<h4>Introduction</h4>Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.<h4>Patients and methods</h4>Tumor tissue from 257 patients with ER-positive breast cancer treated with tamoxifen was used for determination of the best threshold for i  ...[more]

Similar Datasets

| S-EPMC10564809 | biostudies-literature
| S-EPMC4326646 | biostudies-literature
| S-EPMC8661243 | biostudies-literature
| S-EPMC5527786 | biostudies-other
| S-EPMC5356693 | biostudies-literature
| S-EPMC7418366 | biostudies-literature
| S-EPMC9097586 | biostudies-literature
| S-EPMC6923975 | biostudies-literature
| S-EPMC6825343 | biostudies-literature
| S-EPMC5527163 | biostudies-literature